Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR)

Inclusion Criteria

• •\- Participant must be 18 years of age or older, at the time of signing the informed consent.
• •\- Confirmed diagnosis of CRSwNP for at least 12 months prior to routine care visit 1.
• •\- Stable standard of care (SoC) treatment with Intranasal corticosteroids (INCS) for CRSwNP for at least 30 days prior to routine care visit 1.
• •\- Physician decision that participant is eligible for treatment with Tezepelumab according to locally approved CRSwNP label.
• •Participants must be able and willing to read and comprehend written instructions, to collect Patient-reported outcome (PROs) and medication intake via app or alternative mode (paper) and to sign the informed consent document. Use of the mobile app is optional; participants without smartphones will not be excluded. Mode of data capture will be recorded and adjusted for in analyses where relevant.
• •\- Participants who will be enrolled after index date need to have at least one measurement for SNOT-22 prior (within a maximum of 4 weeks) to index date.
• •\- -